pumecitinib nasal spray (PG-011 nasal spray) / Prime Gene Therap - LARVOL DELTA

A Phase III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis (clinicaltrials.gov) - P3 | N=600 | Not yet recruiting | Sponsor: Prime Gene Therapeutics Co., Ltd.

New P3 trial • Allergic Rhinitis • Immunology • Inflammation

A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults with Moderate to Severe Seasonal Allergic Rhinitis (ChiCTR) - P2/3 | N=760 | Recruiting | Sponsor: Beijing Tongren Hospital, Capital Medical University; Beijing Tongren Hospital, Capital Medical University | Phase classification: P2 ➔ P2/3 | N=160 ➔ 760

Enrollment change • Phase classification • Allergic Rhinitis • Immunology • Inflammation

A dose-exploratory Phase II clinical study to study the safety, efficacy, and pharmacokinetic profile of PG-011 nasal spray in moderate-to-severe seasonal allergic rhinitis (ChiCTR) - P2 | N=160 | Completed | Sponsor: Beijing Tongren Hospital, Capital Medical University; Beijing Tongren Hospital, Capital Medical University | Recruiting ➔ Completed

Trial completion • Allergic Rhinitis • Immunology • Inflammation

Safety and pharmacokinetics of PG-011 nasal spray (ChiCTR) - P1 | N=90 | Completed | Sponsor: Shulan (Hangzhou) Hospital; Shulan (Hangzhou) Hospital | Not yet recruiting ➔ Completed | N=150 ➔ 90

Enrollment change • Trial completion • Allergic Rhinitis • Immunology • Inflammation

A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis (clinicaltrials.gov) - P2 | N=160 | Active, not recruiting | Sponsor: Prime Gene Therapeutics Co., Ltd. | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Jan 2026 ➔ May 2026

Enrollment closed • Trial completion date • Allergic Rhinitis • Immunology • Inflammation

A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults with Moderate to Severe Seasonal Allergic Rhinitis (ChiCTR) - P2 | N=160 | Recruiting | Sponsor: Beijing Tongren Hospital, Capital Medical University; Beijing Tongren Hospital, Capital Medical University

New P2 trial • Allergic Rhinitis • Immunology • Inflammation

Pumecitinib: A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis (clinicaltrials.gov) - P2 | N=160 | Not yet recruiting | Sponsor: Prime Gene Therapeutics Co., Ltd.

New P2 trial • Allergic Rhinitis • Immunology • Inflammation